57802-79-6

Usage

Uses

Used in Pharmaceutical Industry:
4-N-Butylbenzylamine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and enhance their therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-N-Butylbenzylamine serves as an essential component in the production of agrochemical products, aiding in the creation of effective solutions for agricultural applications.
Used in Dye Industry:
4-N-Butylbenzylamine is utilized as an intermediate in the manufacturing process of dyes, contributing to the development of a wide range of colorants for various industries.
Used in Surfactant Production:
This chemical is employed as a crucial intermediate in the production of surfactants, which are used in a multitude of applications, including detergents, cleaners, and personal care products, due to their ability to reduce surface tension and stabilize emulsions.
Used in Organic Chemical Synthesis:
4-N-Butylbenzylamine is used as a versatile building block in the synthesis of other organic chemicals, enabling the creation of a diverse array of compounds for various applications across different industries.

InChI:InChI=1/C11H17N/c1-2-3-4-10-5-7-11(9-12)8-6-10/h5-8H,2-4,9,12H2,1H3/p+1

Upstream product

• 1200-14-2 4-(n-butyl)benzaldehyde 
• 107377-07-1 4-n-butylbenzamide 

Downstream Products

• 1418008-75-9 C₂₂H₂₅FeN 
• 223490-91-3 (3-{[(4-butyl-benzyl)-(1-methyl-1H-imidazole-4-sulfonyl)-amino]-methyl}-phenyl)-acetic acid methyl ester 
• 1394122-50-9 C₃₂H₄₇N₇O₂S 
• 210115-56-3 {3-[(4-butyl-benzylamino)-methyl]-phenyl}-acetic acid methyl ester 

Relevant academic research and scientific papers

Mechanistic Study and Development of Catalytic Reactions of Sm(II)

Samarium diiodide (SmI2) is one of the most widely used single-electron reductants available to organic chemists because it is effective in reducing and coupling a wide range of functional groups. Despite the broad utility and application of SmI2 in synthesis, the reagent is used in stoichiometric amounts and has a high molecular weight, resulting in a large amount of material being used for reactions requiring one or more equivalents of electrons. Although few approaches to develop catalytic reactions have been designed, they are not widely used or require specialized conditions. As a consequence, general solutions to develop catalytic reactions of Sm(II) remain elusive. Herein, we report mechanistic studies on catalytic reactions of Sm(II) employing a terminal magnesium reductant and trimethylsilyl chloride in concert with a noncoordinating proton donor source. Reactions using this approach permitted reductions with as little as 1 mol % Sm. Mechanistic studies provide strong evidence that during the reaction, SmI2 transforms into SmCl2, therefore broadening the scope of accessible reactions. Furthermore, this mechanistic approach enabled catalysis employing HMPA as a ligand, facilitating the development of catalytic Sm(II) 5-exo-trig ketyl olefin cyclization reactions. The initial work described herein will enable further development of both useful and user-friendly catalytic reactions, a long-standing, but elusive goal in Sm(II) chemistry.

Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus

This invention provides compounds of formula (IIA) and pharmaceutical compositions thereof, where M, a, b, and R1-R5 are as defined herein, for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes. Pharmaceutical compositions comprising the compounds of formula (IIA) are also disclosed.

New efficient substrates for semicarbazide-sensitive amine oxidase/VAP-1 enzyme: Analysis by SARs and computational docking

Structure activity relationships for semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) were studied using a library of arylalkylamine substrates, with the aim of contributing to the discovery of more efficient SSAO substrates. Experimental data were contrasted with computational docking studies, thereby allowing us to examine the mechanism and substrate-binding affinity of SSAO and thus contribute to the discovery of more efficient SSAO substrates and provide a structural basis for their interactions. We also built a model of the mouse SSAO structure, which provides several structural rationales for interspecies differences in SSAO substrate selectivity and reveals new trends in SSAO substrate recognition. In this context, we identified novel efficient substrates for human SSAO that can be used as a lead for the discovery of antidiabetic agents.

Antiatherosclerotic ureas and thioureas

This invention is concerned with ureas and thioureas which may be represented by the formula: STR1 wherein X represents at least one substituent selected from the group consisting of (C1 -C4)alkyl, (C1 -C4)alken